A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma

被引:41
作者
Warttinger, U. [1 ]
Giese, C. [1 ]
Harenberg, J. [2 ]
Holmer, Erik [3 ]
Kraemer, Roland [1 ]
机构
[1] Heidelberg Univ, Inst Inorgan Chem, Neuenheimer Feld 270, D-60129 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Maybachstr 14, D-68169 Mannheim, Germany
[3] Dilafor AB, Karolinska Inst Sci Pk,Fogdevreten 2A, SE-17165 Solna, Sweden
关键词
Heparin Red; Assay; Non-anticoagulant heparins; Fluorescent; Plasma; Tafoxiparin; BINDING;
D O I
10.1007/s00216-016-9940-y
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Heparins are widely used anticoagulant drugs. The current monitoring practice for heparin in plasma, such as the chromogenic anti-factor Xa assay, relies on heparin-triggered activation of antithrombin, an inhibitor of coagulation proteases. Such assays are not applicable to the detection of non-anticoagulant heparins, an emerging class of drug candidates for therapeutic applications unrelated to anticlotting activity. This study describes the application of a commercially available fluorescent probe assay (Heparin Red) for the direct and sensitive detection of the "chemical" heparin in plasma, independent of any anticoagulant activity. The quantification range is about 0-5 mu g/mL for both unfractionated heparin (corresponding to 0-1 IU/mL) and the low molecular weight heparin enoxaparin. The Heparin Red assay is of particular value for the quantification of non-anticoagulant heparins, as exemplified by the low molecular weight heparin derivative tafoxiparin and a N-desulfated-N-reacetylated heparin. Heparin octa- and decasaccharides are also detected.
引用
收藏
页码:8241 / 8251
页数:11
相关论文
共 24 条
[1]  
[Anonymous], COAM HEP
[2]  
[Anonymous], NONANTICOAGULANT ACT
[3]  
[Anonymous], HEP OL
[4]  
[Anonymous], ISRN PHARM
[5]   Guidelines on the use and monitoring of heparin [J].
Baglin, T ;
Barrowcliffe, TW ;
Cohen, A ;
Greaves, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (01) :19-34
[6]   Structural features of low-molecular-weight heparins affecting their affinity to antithrombin [J].
Bisio, Antonella ;
Vecchietti, Davide ;
Citterio, Laura ;
Guerrini, Marco ;
Raman, Rahul ;
Bertini, Sabrina ;
Eisele, Giorgio ;
Naggi, Annamaria ;
Sasisekharan, Ram ;
Torri, Giangiacomo .
THROMBOSIS AND HAEMOSTASIS, 2009, 102 (05) :865-873
[7]   Heparin sensing and binding - taking supramolecular chemistry towards clinical applications [J].
Bromfield, Stephen M. ;
Wilde, Ellis ;
Smith, David K. .
CHEMICAL SOCIETY REVIEWS, 2013, 42 (23) :9184-9195
[8]  
Cassinelli G, 2016, INT J CARDIOL, V212, pS14, DOI 10.1016/S0167-5273(16)12004-2
[9]   Low molecular weight heparin stimulates myometrial contractility and cervical remodeling in vitro [J].
Ekman-Ordeberg, Gunvor ;
Hellgren, Margareta ;
Akerud, Anna ;
Andersson, Eva ;
Dubicke, Aurelija ;
Sennstrom, Maria ;
Bystrom, Birgitta ;
Tzortzatos, Gerasimos ;
Gomez, Maria F. ;
Edlund, Mans ;
Lindahl, Ulf ;
Malmstrom, Anders .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2009, 88 (09) :984-989
[10]   Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study [J].
Galli, Monica ;
Magen, Hila ;
Einsele, Hermann ;
Chatterjee, Manik ;
Grasso, Mariella ;
Specchia, Giorgina ;
Barbieri, Paola ;
Paoletti, David ;
Pace, Silvia ;
Sanderson, Ralph D. ;
Rambaldi, Alessandro ;
Nagler, Arnon .
BLOOD, 2015, 126 (23)